Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,158.57 +30.78 (+0.60%) Dow
38,732.19 +56.51 (+0.15%) Nasdaq
16,278.47 +122.15 (+0.76%) Bitcoin USD
63,649.31 -927.52 (-1.44%) CMC Crypto 200
1,368.06 +55.44 (+4.22%)
Eli Lilly and Co (LLY.BE)
| Previous close | 698.00 |
| Open | 687.00 |
| Bid | 696.70 x 0 |
| Ask | 698.40 x 0 |
| Day's range | 687.00 - 687.00 |
| 52-week range | 385.00 - 736.50 |
| Volume | |
| Avg. volume | 14 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
